Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
Abstract Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) pathway is a powerful tool to combat tumor growth and progression; however, drug resistance frequently emerges. We identify CD5L (CD5 antigen-like precursor) as an important gene upregulated in response to anti...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2023-04-01
|
| Seri Bilgileri: | Nature Communications |
| Online Erişim: | https://doi.org/10.1038/s41467-023-36910-5 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
